A Randomized, Double-Blind, Parallel Group Study to Compare Discontinuation Symptoms in Abrupt Discontinuation Versus a 1-Week Tapering Regimen in Subjects With MDD Treated for 24 Weeks With Open-label 50 mg DVS SR Formulation.

Trial Profile

A Randomized, Double-Blind, Parallel Group Study to Compare Discontinuation Symptoms in Abrupt Discontinuation Versus a 1-Week Tapering Regimen in Subjects With MDD Treated for 24 Weeks With Open-label 50 mg DVS SR Formulation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Apr 2014

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 08 Apr 2014 Results published in the Journal of Clinical Psychopharmacology.
    • 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
    • 14 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top